Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  +6.00p +4.54% 138.25p 852 16:35:14
Bid Price Offer Price High Price Low Price Open Price
134.00p 142.50p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.02 -3.78 -2.30 96.8

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
11/9/201816:09Silence Therapeutics (the old SR Pharma)47,589
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52
05/10/201620:29port-
29/5/201310:32Silence Therapeutics - news and views1,412
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:59:58140.00500700.00O
11:58:58140.00352492.80O
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

DateSubject
20/9/2018
09:20
Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 132.25p.
Silence Ther. has a 4 week average price of 132.25p and a 12 week average price of 110p.
The 1 year high share price is 254.75p while the 1 year low share price is currently 110p.
There are currently 70,021,624 shares in issue and the average daily traded volume is 6,007 shares. The market capitalisation of Silence Ther. is £96,804,895.18.
03/8/2018
14:10
tshirley12: Could anyone tell me what has happened in the last couple of weeks for the share price to have dropped about 40 points,or nearly 25%.
06/3/2018
08:32
1gw: I missed the Nasdaq reference at first glance. Interesting. I get the impression this is a management team with more than half an eye focused on the share price and the potential to support the price with the carefully managed release of information.
04/12/2017
08:30
1gw: Nice bit of profit-taking on the arwr stake. I wonder what that will do to the arwr share price today? And whether it's all part of the game to get some meaningful dialogue going with arwr?
28/9/2017
08:23
rogen83: Arrowhead stake now worth £20m or 30p of SLNs share price Good work Ali
07/9/2017
14:36
1gw: It has at least put the brakes on the share price. Who knows - if there's any truth to the suggestions that Alnylam might look to settle the patent dispute by taking over Silence then now might be a good time to strike. Certainly it seemed to me from the Alnylam call that Alnylam see the Fitusiran death as tragic but by no means an end to their hopes for the drug.
29/8/2017
09:55
1gw: Anybody any thoughts as to why this rise doesn't seem to have caught the attention and imagination of the day trader crowd? Isn't biotech almost as good as oil/minerals for generating hype, excitement and exaggerated share price moves?
24/8/2017
15:24
1gw: I can't help feeling there's an element of SLN investors looking at the ARWR price trajectory and thinking something's happening - and ARWR investors looking at the SLN price trajectory and thinking the same. Hopefully there's some substance behind both moves rather than mutually reinforcing illusions...
21/8/2017
16:19
1gw: I am surprised we haven't had a rush of short-term players to the bulletin boards, given the share price chart. All the better for the future, perhaps, if the share price has done what it has done without much input from the bulletin boards or twitter.
04/5/2017
16:00
1gw: ARWR is up around 20% this afternoon - not enough to take me into profit on my holding, but makes the loss look a little less severe. They beat on revenue and earnings, thanks (I think) to the Amgen up-front payments, and also announced an analyst R&D day for September to explain what they're doing. They described the Amgen partnership as working well and said in response to a question that they were interested in similar partnerships with other companies and are optimistic that they can enter into additional strategic partnerships. No obvious follow-through to the SLN share price yet, but perhaps ARWR's spike (on heavy volume) will draw some attention to other companies in the sector.
03/5/2017
14:17
1gw: Well let's hope the ARWR call this evening will be a material event! It's a good point on cash vs market cap/EV. According to the preliminaries, at 31st December they held: £39.0m cash & equivalents £4.4m available-for-sale financial assets (mainly ARWR shares) So £43.4m between the two categories. With about 70m shares in issue that's equivalent to about 62p in cash/equivalents and financial assets. Since year-end they've converted some of the cash into more ARWR shares and they will have burnt through some more cash in running the business. But even so, with a share price in the 70's that's not a lot for the ongoing business, IP, R&D and pipeline. Which is hard to reconcile with Ali's upbeat comments on valuation of RNA therapeutics, for example, in the RNS on the ARWR purchase: "We believe that the recent technological advancements in RNA therapeutics have been underestimated and undervalued. We are confident that the recent market approval of medicines in our field are the beginning of the emergence of an important new class of therapeutics. " So I've bought a third tranche this afternoon - registering as a buy this time.
Silence Therapeutics share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20180920 19:56:16